7.59

4.69% 0.34

Achieve Life Sciences Inc (ACHV)

Overview News Price History Option Chain Financials Why ACHV Down? Discussions Forecast Stock Split

Achieve Life Sciences Inc stock is traded at $7.59, with a volume of 1.74M. It is up +4.69% in the last 24 hours and up +20.29% over the past month. Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Previous Close:

$7.25

Open:

$7.27

24h Volume:

1.74M

Relative Volume:

0.97

Market Cap:

$779.18M

Revenue:

Net Income/Loss:

$-51.99M

P/E Ratio:

-6.8041

EPS:

-1.1155

Net Cash Flow:

$-45.31M

1W Performance:

+14.14%

1M Performance:

+20.29%

6M Performance:

+80.71%

1Y Performance:

+197.65%

1-Day Range:

$7.15

$7.60

1-Week Range:

$6.51

$7.60

52-Week Range:

$2.4601

$7.60

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Name

Achieve Life Sciences Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

425-686-1500

Address

22722 29TH DR. SE, SEATTLE, BC

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ACHV's Discussions on Twitter

Compare ACHV vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACHV Achieve Life Sciences Inc	7.59	686.79M	0	-51.99M	-45.31M	-1.1155
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Nov-25-25	Initiated	Citizens JMP	Mkt Outperform
Aug-21-25	Initiated	H.C. Wainwright	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Sep-27-24	Initiated	Raymond James	Strong Buy
May-10-23	Reiterated	Maxim Group	Buy
Jun-23-21	Initiated	Oppenheimer	Outperform

View All

Achieve Life Sciences Inc Stock (ACHV) Latest News

01:10 AM

Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Lowered by Wall Street Zen - MarketBeat

01:10 AM

Aug 14, 2026

Achieve Life SciencesEnters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock - TradingView

Aug 14, 2026

Achieve Life Sciences (ACHV) launches $150M at-the-market stock program - Stock Titan

Aug 14, 2026

Achieve Life Sciences, Inc. (NASDAQ:ACHV): Is Breakeven Near? - simplywall.st

Aug 14, 2026

(08/14/26) ACHV: A Speculative Trade in the Biotech Sector - moneyshow.com

Aug 14, 2026

Aug 13, 2026

Janus Henderson Group (ACHV) reports 5,502,064 Achieve Life shares under management - Stock Titan

Aug 13, 2026

This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - benzinga.com

Aug 13, 2026

Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says - marketscreener.com

Aug 13, 2026

Achieve Life Sciences, Inc. Stock 12‑Month Price Target Cut to $13.83, Implies 107% Upside - TradingView

Aug 13, 2026

Achieve Life Sciences (NASDAQ:ACHV) Hits New 12-Month HighHere's Why - MarketBeat

Aug 13, 2026

Morgan Stanley Initiates Achieve Life Sciences at Overweight, With $13 Price Target - marketscreener.com

Aug 13, 2026

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit. - webull.com

Aug 13, 2026

Morgan Stanley initiates Achieve Life Sciences stock at overweight By Investing.com - Investing.com Nigeria

Aug 13, 2026

Morgan Stanley initiates Achieve Life Sciences stock at overweight - Investing.com

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright reiterates Achieve Life Sciences stock rating at buy By Investing.com - Investing.com Canada

Aug 12, 2026

Research Analysts Set Expectations for ACHV FY2028 Earnings - MarketBeat

Aug 12, 2026

Aug 11, 2026

Achieve Life Sciences Releases Q2 2026 Financial Results - AlphaStreet

Aug 11, 2026

ACHIEVE LIFE SCIENCES, INC. 6M 2026: Net loss $(84.9)M, EPS $(1.15) — 10-Q Summary - TradingView

Aug 11, 2026

Achieve Life Sciences (ACHV) swings to larger $84.9M loss on warrant costs - Stock Titan

Aug 11, 2026

Achieve Life Sciences (NASDAQ: ACHV) posts larger Q2 2026 loss but secures $354M financing - Stock Titan

Aug 11, 2026

Achieve Life Sciences Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 11, 2026

Achieve Life Sciences (NASDAQ:ACHV) Posts Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat

Aug 11, 2026

Achieve Life Sciences (ACHV) Advances Cytisinicline Commercialization Amid Mixed Valuation Signals - GuruFocus

Aug 11, 2026

Achieve's Cytisinicline Study Finds 24.4% Abstinence vs. 15.8% Placebo - Stock Titan

Aug 11, 2026

Achieve Life Sciences (ACHV) Earnings Date and Reports 2026 - MarketBeat

Aug 11, 2026

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Aug 11, 2026

Aug 10, 2026

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Achieve Life Sciences (ACHV) - The Globe and Mail

Aug 10, 2026

Aug 07, 2026